TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
暂无分享,去创建一个
Christopher H Contag | Horst Buerger | Heike Pospisil | Burkhard H Brandt | H. Pospisil | Sheng-Yung P. Chang | C. Contag | B. Brandt | Alice Wang | K. Bartkowiak | H. Buerger | M. Helms | D. Kemming | Mike W Helms | Dirk Kemming | Kai Bartkowiak | Alice Wang | Sheng-Yung Chang
[1] P. V. van Diest,et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.
[2] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[3] G. Assmann,et al. c‐erbB‐2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] A. Miyauchi,et al. Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. , 2005, Cancer letters.
[5] Toru Suzuki,et al. Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. , 2003, Cancer letters.
[6] J. Farndon,et al. EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.
[7] J. Nesland,et al. EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.
[8] Toru Suzuki,et al. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. , 2002, Genes & development.
[9] S. Eccles,et al. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[10] G. Sauter,et al. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. , 2005, Endocrine-related cancer.
[11] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[12] S. Eccles. The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.
[13] N. Hynes,et al. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling , 1995, Molecular and cellular biology.
[14] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[15] Amanda Y. Chan,et al. EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism , 2004, Clinical & Experimental Metastasis.
[16] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[17] E. Nishida,et al. Identification of the Anti-proliferative Protein Tob as a MAPK Substrate* , 2002, The Journal of Biological Chemistry.
[18] Naoto Hirano,et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells , 2001, Nature Immunology.
[19] M. Toi,et al. Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study , 2004, Breast Cancer Research and Treatment.
[20] C. Jackisch,et al. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. , 1998, The American journal of pathology.
[21] C. Osborne,et al. HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[22] A. Ruíz,et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. , 1997, Clinica chimica acta; international journal of clinical chemistry.
[23] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] S. Tsutsui,et al. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. , 2003, Surgery.
[25] Y. Nakamura,et al. Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. , 1996, Oncogene.
[26] Jan Mous,et al. Touching base , 2000, Nature Genetics.
[27] W. Muller,et al. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. , 1999, Experimental cell research.
[28] A. Wells,et al. Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44 , 1996, Clinical & Experimental Metastasis.
[29] M. Greene,et al. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[30] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Noda,et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. , 2003, Genes & development.
[32] Thomas Dittmar,et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c‐erbB‐2 receptor via epidermal growth factor receptor , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] M. Kraus,et al. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. , 1989, Oncogene.
[34] W. Dougall,et al. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[35] Suo,et al. Type 1 protein tyrosine kinases in benign and malignant breast lesions , 1998, Histopathology.
[36] Aaron P. Campbell,et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[38] S. Hirohashi,et al. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. , 1996, Oncogene.
[39] W. E. Gye,et al. CANCER RESEARCH , 1923, British medical journal.
[40] Toru Suzuki,et al. Nuclear localization of Tob is important for regulation of its antiproliferative activity , 2004, Oncogene.
[41] J. R. Reeves,et al. Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.
[42] K. Fujikawa,et al. The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.
[43] M. Noda,et al. Enhancing Effect of Tob Deficiency on Bone Formation Is Specific to Bone Morphogenetic Protein‐Induced Osteogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[44] H Buerger,et al. Tissue microarrays: a new approach for quality control in immunohistochemistry , 2002, Journal of clinical pathology.
[45] H. P. Fell,et al. The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.
[46] D. Kwiatkowski,et al. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] J. Feldner,et al. Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. , 2002, Experimental cell research.
[48] G. Giacco,et al. Prognosis in node-negative breast cancer , 2005, Breast Cancer Research and Treatment.